Manthan 2010 Inaugurated in a Glittering Event

Mumbai, India (PressExposure) January 14, 2010 -- Manthan 2010, the three day international healthcare symposium on "Current Advances in Parenteral and Novel Drug Development" was inaugurated today amongst a glittering gathering of guests from the pharmaceutical industry and the government. The symposium will be accompanied with workshops on "Good Laboratory Practices" and " High Performance Liquid Chromatography (HPLC)" on January 15 and 16, 2010.

The symposium was inaugurated by Prof. Y K Gupta, Head department of Pharmacology, AIIMS.

Manthan 2010 is being organized with an objective to provide an opportunity to the industry, scientific community and regulatory agencies to come together to discuss new initiatives with the purpose of finding a better way of developing new drugs and also improving the quality of existing drug products.

Speaking to the media Chief guest Prof. Y K Gupta, said," India is a global hub for clinical research activity with the fourth largest pool of medical professionals in the world and the largest genetically diverse population in any single country. There is a need to review and design Good Clinical Practices (GCP) guidelines and regulations to conduct clinical trials in accordance with International Community for Harmonisation (ICH) guidelines." His talk elaborated on the challenges, nascent Indian clinical research industry is going to face in a short span of time to be at par with international standards.

Manthan 2010 is organized by Venus Medicine Research Centre (VMRC), the research and development wing of Venus Remedies Ltd, a prominent Indian pharma company.

Dr. (Mrs.) Manu Chaudhary, Deputy Managing Director and Director Research Venus Remedies spoke on various aspects of drug development process, techniques and challenges. "The message of GCP should not be limited upto the pharma industry level, but it needs to percolate down to clinical research fraternity for example investigators, clinical research Associates (CRAs), staff, who are instrumental in following up the GCP guidelines."

Dr Gilbert Wenzel, Director, Venus Remedies Ltd, while addressing the delegates of Manthan2010 focused on portfolio management and short development times - two key factors of success in pharmaceutical drug development. Dr. Wenzel has been former director at Novartis and McKinsey & Co.

The symposium will focus on the need for Novel Drug Development Technologies with an emphasis on nano technology, target based delivery, drug Implants, the bottle necks of existing drug development techniques, national and international regulatory aspects, challenges in Pharma industry with respect to IPR protection, Industry-Academic collaboration, means of reducing R&D time lines and cost, developmental challenges with reference to clinical development aspects.

Among other eminent speakers from pharma & medical fraternity present during inaugural day of Manthan2010 were World renowned cardiovascular research scientist Prof. Pawan Singal, Director, Institute of Cardiovascular Sciences, St. Boniface,Canada , Dr. D.K.Agarwal Scientist - F and WHO-TDR GLP Network Regional Coordinator (Asia)Indian Institute of Toxicology Research, Dr. Sudhir Srivastava , trained as a GLP trainer by the WHO, Geneva in 2001 & trained as a GLP Inspector by the OECD, France and DST, New Delhi, a renowned GLP Consultant and Former Head, Toxicology Division Central Drug Research Institute, Lucknow.

About Venus Remedies India

Venus Remedies India is a research and development driven, pharmaceutical manufacturing company. Among the top 50 Indian Pharma companies of India, the company has out paced most Indian pharmaceutical companies in its growth and value creation over the past few years.
Driven by a top class team of mangers and motivators this organization is counted as one of the most professional companies of India and a preferred place for top innovators and mangers to join the bandwagon of the globally significant Indian Pharma industry.

The company has two manufacturing locations in India and one in Germany. Venus is top class manufacturer of Oncological and Cephalosporin Injectable products following EU-GMP norms for all is activities.
Venus has a broad range of products catering to critical care segment in parenterals like cephalosporins, carbapenems and oncology drugs in lyophilized form, infusions and small volume parenterals .

Venus Remedies has targeted to achieve a turnover of Rs 500 crore and is aiming to be amongst the top 25 pharmaceutical Companies in India by 2012.

Press Release Source:

Press Release Submitted On: January 14, 2010 at 4:38 am
This article has been viewed 16356 time(s).